David S. Tierney

David S. Tierney, listed as board member, has filed trades across 6 companies (mainly through SEC (Form 4)), most often in Catalyst Pharmaceuticals, Inc., Seelos Therapeutics, Inc. and Zevra Therapeutics, Inc. In total, 72 filings cover trades dated from 2 February 2006 to 15 July 2026.

In open-market terms, that means 15 purchases worth €191k on one side and 8 sales worth €2.7M on the other. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 16 share grants and 30 option exercises.

Half of the purchases are above €8,216 and half below. On 7 out of 9 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 10 purchases old enough to measure, the stock rose over the following 90 days in 40% of cases; the median change was -10.2%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 17 July 2026, reports a transaction of €10.6M in Catalyst Pharmaceuticals, Inc. The most recent open-market purchase was published on 13 March 2023, 1,321 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.